Montelukast sodium chewable

×

Overview

What is Montelukast sodium chewable?

Montelukast sodium, USP is the active ingredient in montelukast sodium chewable tablets, is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene CysLT receptor.

Montelukast sodium, USP is described chemically as [-()]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid, monosodium salt.

The empirical formula is CHClNNaOS, and its molecular weight is 608.18. The structural formula is:

Montelukast sodium, USP is a hygroscopic, optically active light yellow colored powder. Montelukast sodium, USP is freely soluble in ethanol, methanol, and water and practically insoluble in acetonitrile. Each 4-mg and 5-mg montelukast sodium chewable tablet contains 4.2 and 5.2 mg montelukast sodium, respectively, which are equivalent to 4 and 5 mg of montelukast, respectively. Both chewable tablets contain the following inactive ingredients: aspartame, colloidal silicon dioxide, croscarmellose sodium, hydroxypropyl cellulose, magnesium stearate, mannitol, microcrystalline cellulose, red ferric oxide, and strawberry flavor.

What does Montelukast sodium chewable look like?

What are the available doses of Montelukast sodium chewable?

What should I talk to my health care provider before I take Montelukast sodium chewable?

How should I use Montelukast sodium chewable?

Montelukast sodium chewable tablets are indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 2 years of age and older.

Montelukast sodium chewable tablets should be taken once daily in the evening. The following doses are recommended: For adults and adolescents 15 years of age and older: 10-mg.

For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.

For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet.

Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established.

There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

What interacts with Montelukast sodium chewable?

Sorry No Records found

What are the warnings of Montelukast sodium chewable?

Sorry No Records found

What are the precautions of Montelukast sodium chewable?

Sorry No Records found

What are the side effects of Montelukast sodium chewable?

Sorry No records found

What should I look out for while using Montelukast sodium chewable?

Hypersensitivity to any component of this product ().

What might happen if I take too much Montelukast sodium chewable?

No specific information is available on the treatment of overdosage with montelukast sodium. In chronic asthma studies, montelukast has been administered at doses up to 200 mg/day to adult patients for 22 weeks and, in short-term studies, up to 900 mg/day to patients for approximately a week without clinically important adverse experiences. In the event of overdose, it is reasonable to employ the usual supportive measures; e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute supportive therapy, if required. There have been reports of acute overdosage in post-marketing experience and clinical studies with montelukast sodium. These include reports in adults and children with a dose as high as 1000 mg. The clinical and laboratory findings observed were consistent with the safety profile in adults and pediatric patients. There were no adverse experiences in the majority of overdosage reports. The most frequently occurring adverse experiences were consistent with the safety profile of montelukast sodium and included abdominal pain, somnolence, thirst, headache, vomiting and psychomotor hyperactivity. It is not known whether montelukast is removed by peritoneal dialysis or hemodialysis.

How should I store and handle Montelukast sodium chewable?

Receipt, transfer, handling, possession, or use of this product is subject to the radioactive material regulations and licensing requirements of the U.S. Nuclear Regulatory Commission, Agreement States or Licensing States as appropriate.Montelukast sodium chewable tablets 4 mg are pink, mottled, oval shaped, uncoated, flat face beveled edge tablets with "C" debossed on one side and "B5" on the other side having a characterstic flavor. Bottle of 30’s 59746-358-30 Bottle of 90’s 59746-358-90 Bottle of 100’s 59746-358-01 Bottle of 500’s 59746-358-05 Bottle of 1000’s 59746-358-10 Blister of 10’s 59746-358-12 Carton of 3x10's 59746-358-32 Montelukast sodium chewable tablets 5 mg are pink, mottled, round, uncoated, flat face beveled edge tablets with "C" debossed on one side and "B6" on the other side having a characterstic flavor. Bottle of 30’s 59746-359-30 Bottle of 90’s 59746-359-90 Bottle of 100’s 59746-359-01 Bottle of 500’s 59746-359-05 Bottle of 1000’s 59746-359-10 Blister of 10’s 59746-359-12 Carton of 3x10's 59746-359-32StorageStore montelukast sodium chewable tablets 4-mg and 5-mg at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Protect from moisture and light. Store in original package.Montelukast sodium chewable tablets 4 mg are pink, mottled, oval shaped, uncoated, flat face beveled edge tablets with "C" debossed on one side and "B5" on the other side having a characterstic flavor. Bottle of 30’s 59746-358-30 Bottle of 90’s 59746-358-90 Bottle of 100’s 59746-358-01 Bottle of 500’s 59746-358-05 Bottle of 1000’s 59746-358-10 Blister of 10’s 59746-358-12 Carton of 3x10's 59746-358-32 Montelukast sodium chewable tablets 5 mg are pink, mottled, round, uncoated, flat face beveled edge tablets with "C" debossed on one side and "B6" on the other side having a characterstic flavor. Bottle of 30’s 59746-359-30 Bottle of 90’s 59746-359-90 Bottle of 100’s 59746-359-01 Bottle of 500’s 59746-359-05 Bottle of 1000’s 59746-359-10 Blister of 10’s 59746-359-12 Carton of 3x10's 59746-359-32StorageStore montelukast sodium chewable tablets 4-mg and 5-mg at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Protect from moisture and light. Store in original package.Montelukast sodium chewable tablets 4 mg are pink, mottled, oval shaped, uncoated, flat face beveled edge tablets with "C" debossed on one side and "B5" on the other side having a characterstic flavor. Bottle of 30’s 59746-358-30 Bottle of 90’s 59746-358-90 Bottle of 100’s 59746-358-01 Bottle of 500’s 59746-358-05 Bottle of 1000’s 59746-358-10 Blister of 10’s 59746-358-12 Carton of 3x10's 59746-358-32 Montelukast sodium chewable tablets 5 mg are pink, mottled, round, uncoated, flat face beveled edge tablets with "C" debossed on one side and "B6" on the other side having a characterstic flavor. Bottle of 30’s 59746-359-30 Bottle of 90’s 59746-359-90 Bottle of 100’s 59746-359-01 Bottle of 500’s 59746-359-05 Bottle of 1000’s 59746-359-10 Blister of 10’s 59746-359-12 Carton of 3x10's 59746-359-32StorageStore montelukast sodium chewable tablets 4-mg and 5-mg at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Protect from moisture and light. Store in original package.Montelukast sodium chewable tablets 4 mg are pink, mottled, oval shaped, uncoated, flat face beveled edge tablets with "C" debossed on one side and "B5" on the other side having a characterstic flavor. Bottle of 30’s 59746-358-30 Bottle of 90’s 59746-358-90 Bottle of 100’s 59746-358-01 Bottle of 500’s 59746-358-05 Bottle of 1000’s 59746-358-10 Blister of 10’s 59746-358-12 Carton of 3x10's 59746-358-32 Montelukast sodium chewable tablets 5 mg are pink, mottled, round, uncoated, flat face beveled edge tablets with "C" debossed on one side and "B6" on the other side having a characterstic flavor. Bottle of 30’s 59746-359-30 Bottle of 90’s 59746-359-90 Bottle of 100’s 59746-359-01 Bottle of 500’s 59746-359-05 Bottle of 1000’s 59746-359-10 Blister of 10’s 59746-359-12 Carton of 3x10's 59746-359-32StorageStore montelukast sodium chewable tablets 4-mg and 5-mg at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Protect from moisture and light. Store in original package.

×

Clinical Information

Chemical Structure

No Image found

Clinical Pharmacology

The cysteinyl leukotrienes (LTC, LTD, LTE) are products of arachidonic acid metabolism and are released from various cells, including mast cells and eosinophils. These eicosanoids bind to cysteinyl leukotriene (CysLT) receptors. The CysLT type-1 (CysLT) receptor is found in the human airway (including airway smooth muscle cells and airway macrophages) and on other pro-inflammatory cells (including eosinophils and certain myeloid stem cells). CysLTs have been correlated with the pathophysiology of asthma and allergic rhinitis. In asthma, leukotriene-mediated effects include airway edema, smooth muscle contraction, and altered cellular activity associated with the inflammatory process. In allergic rhinitis, CysLTs are released from the nasal mucosa after allergen exposure during both early- and late-phase reactions and are associated with symptoms of allergic rhinitis.

Montelukast is an orally active compound that binds with high affinity and selectivity to the CysLT receptor (in preference to other pharmacologically important airway receptors, such as the prostanoid, cholinergic, or β-adrenergic receptor). Montelukast inhibits physiologic actions of LTD at the CysLT receptor without any agonist activity.

Non-Clinical Toxicology

Hypersensitivity to any component of this product ().

Montelukast sodium is not indicated for use in the reversal of bronchospasm in acute asthma attacks, including status asthmaticus. Patients should be advised to have appropriate rescue medication available. Therapy with montelukast sodium can be continued during acute exacerbations of asthma. Patients who have exacerbations of asthma after exercise should have available for rescue a short-acting inhaled β-agonist.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72

×

Tips

×

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).

Disclaimer: